LeadArt Biotechnologies, a Boston, MA and Ningbo, China-based biotechnology company focused on drug discovery by automating chemoproteomics processes, raised US$6M in Pre-A funding.
The round was led by BlueRun Ventures Aster.
The company intends to use the funds to advance the development of its automated chemoproteomics platform and the creation of a human target-probe database.
Led by CEO Feng Ni, LeadArt Biotechnologies is accelerating drug discovery by automating chemoproteomics processes and creating a human live-cell target-probe database. Its platform integrates biotechnology and automation technologies to discover disease-related targets and chemical probes for traditionally undruggable and unexplored targets.
The company recently signed a strategic collaboration with AstraZeneca’s iCampus to develop a herbal medicine preclinical translation platform in Chengdu, China.
FinSMEs